References

Resources_header_woman
  1. ILUVIEN® [package insert]. Alpharetta, GA: Alimera Sciences, Inc.
  2. Findl O. Intraocular lens materials and design. In: Colvard DM, ed. Achieving Excellence in Cataract Surgery: A Step-by-Step Approach. 2009. http://phaco.ascrs.org/sites/phaco.ascrs.org/files/textbooks/Achieving%20Excellence%20in%20Cataract%20Surgery%20-%20Chapter%2012.pdf. Accessed November 7, 2014.
  3. Campochiaro PA, Brown DM, Pearson A, et al; FAME Study Group. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118(4):626-635.
  4. Data on file. Alimera Sciences, Inc.
  5. Campochiaro PA, Brown DM, Pearson A, et al; Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2012-2132.
  6. Stratton, IM, Kohner, EM, et al. UKPDS 50: Risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia. 2001;44:156-163.
  7. Dong, N, Xu, B, et al. Study of 27 aqueous humor cytokines in patients with type 2 diabetes with or without retinopathy. Molecular Vision. 2013:19:1734-1746.
  8. Diabetes Control and Complications Research Group. The Effect of Intensive Diabetes Treatment on the Progression of Diabetic Retinopathy in Insulin-Dependent Diabetes Mellitus. Arch Ophthalmol. 1995:113:35-51.
  9. Owen LA, Hartnett ME. Soluble mediators of diabetic macular edema: The diagnostic role of aqueous VEGF and cytokine levels in diabetic macular edema. Curr Diab Rep. 2013;13(4):476-480.

Subscribe for Updates

Enter your email address to stay up-to-date on the latest ILUVIEN® news.

  • No Thanks
  • This field is for validation purposes and should be left unchanged.